Streamlining Cardiology Express Scripts Integration for Prior Authorization

Achieving efficient **cardiology Express Scripts integration** is critical for managing the high volume of prior authorizations for specialty cardiovascular medications.

Revenue cycle directors and prior authorization coordinators in cardiology face unique challenges with PBM-driven prior authorizations, particularly for high-cost specialty drugs. Express Scripts, as a major pharmacy benefit manager (PBM) under Evernorth, often requires specific documentation and step therapy adherence for many cardiovascular therapies. Klivira's platform automates these complex workflows, connecting directly to PBM requirements.

Understanding Express Scripts' Role in Cardiology PA

Express Scripts, as a prominent PBM, plays a significant role in managing pharmacy benefits for many cardiovascular patients. Prior authorizations for specialty cardiovascular drugs, such as PCSK9 inhibitors, sacubitril/valsartan, and SGLT2 inhibitors, are frequently routed through their channels, requiring specific clinical criteria and step therapy adherence. Navigating these requirements efficiently is key to patient access and revenue integrity.

Key Cardiology Medications Requiring Express Scripts PA

PCSK9 inhibitors (e.g., for refractory hyperlipidemia)
Sacubitril/valsartan (Entresto) for heart failure with reduced ejection fraction (HFrEF)
SGLT2 inhibitors for heart failure indications
Mavacamten for hypertrophic cardiomyopathy
Select novel anticoagulants in specific populations

Typical Documentation for Express Scripts Cardiology PA

Successful prior authorization submissions to Express Scripts for cardiology medications demand precise documentation. For PCSK9 inhibitors, this often includes LDL levels on maximum tolerated statin therapy plus ezetimibe trial. Sacubitril/valsartan and SGLT2 inhibitors for heart failure require clear documentation of ejection fraction and NYHA functional class. Adherence to ACC/AHA guidelines is implicitly expected, as payer policies often mirror these clinical standards.

Common Prior Authorization Hurdles with Express Scripts

Cardiology practices frequently encounter denials from PBMs like Express Scripts due to issues such as insufficient documentation of optimal medical therapy duration or non-adherence to step therapy protocols. For specialty drugs, a common reason for denial is the lack of documented trials of less expensive, first-line agents, even when clinically appropriate. Klivira’s platform helps pre-empt these issues by flagging missing information.

Klivira's Approach to Cardiology Express Scripts Integration

Automated routing of specialty drug PA requests directly to Express Scripts' channels.
Pre-submission logic applying payer-specific step-therapy criteria for cardiovascular medications.
Integration with EMRs to pull relevant clinical data (e.g., ejection fraction, medication history, lab values).
Proactive identification of documentation gaps before submission to Express Scripts.
Streamlined appeals management for Express Scripts denials.

EMR and Payer Touchpoints in Cardiology Drug PA

Effective **cardiology Express Scripts integration** necessitates seamless data exchange between your EMR and the PBM. Order types for specialty cardiovascular drugs trigger the PA workflow. Klivira integrates with leading EMRs via SMART on FHIR, extracting critical patient data – such as medication history, ejection fraction, and NYHA class – to populate X12 278 or ePA forms, ensuring accurate and complete submissions to Express Scripts via NCPDP SCRIPT standards.

Frequently asked questions

How does Klivira handle step therapy requirements for cardiology drugs with Express Scripts?

Klivira's platform incorporates payer-specific policy logic that includes Express Scripts' step therapy requirements for cardiology medications. Before submission, the system flags if required first-line therapies or trials are not documented, helping prevent denials related to step therapy non-compliance. This proactive approach ensures submissions meet PBM criteria.

Can Klivira integrate with our EMR to pull cardiology-specific data for Express Scripts PAs?

Yes, Klivira integrates with major EMRs, leveraging standards like SMART on FHIR, to extract critical cardiology data. This includes ejection fraction, NYHA functional class, prior medication history, and relevant lab results, which are essential for completing Express Scripts prior authorization requests for specialty cardiovascular drugs.

What types of cardiology medications does Klivira automate PA for with Express Scripts?

Klivira automates prior authorizations for high-volume, high-cost specialty cardiovascular drugs managed by Express Scripts. This includes, but is not limited to, PCSK9 inhibitors, sacubitril/valsartan, SGLT2 inhibitors used for heart failure, and mavacamten, ensuring compliance with PBM-specific criteria.

Does Klivira help with appeals for Express Scripts cardiology PA denials?

Klivira's platform supports the appeals process for Express Scripts cardiology PA denials. It helps identify the root cause of the denial and facilitates the submission of additional clinical documentation or clarification, streamlining the typically complex and time-consuming appeal workflow.

How does Klivira ensure compliance with Express Scripts' specific submission channels?

Klivira automatically routes prior authorization requests to the appropriate Express Scripts channel, whether it's through an electronic prior authorization (ePA) portal using NCPDP SCRIPT standards or other designated pathways. This ensures submissions are sent via the correct method, reducing processing delays and administrative burden.